Raf-B (F-3) PE Antibody sc-55522 PE from Santa Cruz Biotechnology, Inc.

Product Specs
ItemRaf-B (F-3) PE Antibody
CompanySanta Cruz Biotechnology, Inc.
Price $343.00Supplier Page View Company Product Page
Catalog Numbersc-55522 PE
Antibody TypePrimary Antibody Conjugates
Clonalitymonoclonal
Reactivitymouse, rat, human
FormatPurified
ApplicationsWB(RGB), IF, IHC(P), FCM
CloneF-3
IsotypeIgG2a
Hostmouse
Quantity200 µg/ml
TargetRaf-B
NCBI Full Gene NameBraf transforming gene, B-Raf proto-oncogene, serine/threonine kinase
NCBI Gene Aliases9930012E13Rik, C230098H17, Braf2, BRAF1, B-raf, BRAF-1, Braf-2, RAFB1, B-RAF1, D6Ertd631e, NS7
Conjugate/Tagphycoerythrin

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3KMolecular oncologySeptember 1, 2022Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, Fuss C, Schirbel A, Schülein-Völk C, Buchberger A, et al.

(2) BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancersJournal of cellular and molecular medicineJuly 1, 2022Gao Y, Zhang D, Wang F, Zhang D, Li P, Wang K.

(3) Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic TargetInternational journal of molecular sciencesAugust 25, 2021Jung H, Bae K, Lee JY, Kim JH, Han HJ, Yoon HY, Yoon KA.

(4) Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapiesThe Journal of experimental medicineJuly 2, 2018Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, et al.

(5) MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cellsOncogeneFebruary 22, 2018Schroyer AL, Stimes NW, Abi Saab WF, Chadee DN.

(6) SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung CancerCancer researchJune 1, 2017Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, et al.

(7) Targeting NRAS^Q61K mutant delays tumor growth and angiogenesis in non-small cell lung cancerAmerican journal of cancer researchJanuary 1, 2017Song Z, Liu F, Zhang J.

(8) RAP1-mediated MEK/ERK pathway defects in Kabuki syndromeThe Journal of clinical investigationSeptember 1, 2015Bögershausen N, Tsai IC, Pohl E, Kiper PÖ, Beleggia F, Percin EF, Keupp K, Matchan A, Milz E, Alanay Y, et al.

(9) Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genesCancer discoveryDecember 1, 2014Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, et al.

(10) The E3 ligase CHIP mediates ubiquitination and degradation of mixed-lineage kinase 3Molecular and cellular biologyAugust 1, 2014Blessing NA, Brockman AL, Chadee DN.

(11) Modeling tandem AAG8-MEK inhibition in melanoma cellsCancer medicineJune 1, 2014Sun B, Kawahara M, Nagamune T.

(12) The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cellsPloS oneJanuary 1, 2014Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T.

(13) S100P is a novel interaction partner and regulator of IQGAP1The Journal of biological chemistryMarch 4, 2011Heil A, Nazmi AR, Koltzscher M, Poeter M, Austermann J, Assard N, Baudier J, Kaibuchi K, Gerke V.

(14) Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancerOncogeneFebruary 17, 2011Zhan Y, Modi N, Stewart AM, Hieronimus RI, Liu J, Gutmann DH, Chadee DN.

(15) VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancerMolecular and cellular biologyOctober 1, 2010Fernández IF, Blanco S, Lozano J, Lazo PA.

(16) Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E miceOncogeneJune 11, 2009Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Be the First to Write a Review!

Raf-B (F-3) PE Antibody

Raf-B (F-3) PE Antibody from Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

Citations (16)

Reviews

Raf-B (F-3) PE Antibody from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map